Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease

Movement Disorders

Volumn 24, Issue 11, 2009, Pages 1669-1675

  Weise, David ^a   Lorenz, Reinhard ^a   Schliesser, Mira ^a   Schirbel, Andreas ^a   Reiners, Karlheinz ^a   Classen, Joseph ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

CIT SPECT; Neurodegeneration; Parkinson's disease; Transcranial sonography

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; IODINE 123; LEVODOPA;

ADULT; ARTICLE; CLINICAL ARTICLE; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DOPPLER ECHOGRAPHY; FEMALE; FUNCTIONAL DISEASE; HUMAN; IMAGE ANALYSIS; MALE; NERVE CELL DEGENERATION; NERVE DEGENERATION; NERVE PROJECTION; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA;

AGED; ANTIPARKINSON AGENTS; COCAINE; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEURAL PATHWAYS; NEURONS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; SUBSTANTIA NIGRA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 69949175994     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22665     Document Type: Article

References (42)

1. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-2301.
2. Hassler R. Zur Pathologie der paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 1938;48:387-476.
3. Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of Parkinsonism. Mov Disord 2007;22:1229-1238.
4. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008;7:1044-1055.
5. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol 2001;248:684-689.
6. Stockner H, Sojer M, K KS, et al. Midbrain sonography in patients with essential tremor. Mov Disord 2007;22:414-417.
7. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007;130(Pt 7):1799-1807.
8. Berg D, Becker G, Zeiler B, et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999;53:1026-1031.
9. Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry 2005;76: 423-425.
10. Walter U, Klein C, Hilker R, Benecke R, Pramstaller PP, Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 2004;19:1445-1449.
11. Walter U, Dressler D, Probst T, et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol 2007;64:1635-1640.
12. Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol 2008;7:417-424.
13. Stern MB. Transcranial ultrasound in Parkinson's disease. Lancet Neurol 2008;7:376-378.
14. Berg D, Roggendorf W, Schroder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002;59:999-1005.
15. Zecca L, Berg D, Arzberger T, et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005; 20:1278-1285.
16. Spiegel J, Hellwig D, Mollers MO, et al. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006;129(Pt 5):1188-1193.
17. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
18. Neumeyer JL, Wang SY, Milius RA, et al. [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 191;34:3144-3146.
19. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
20. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
21. Walter U, Behnke S, Eyding J, et al. Transcranial brain parenchyma sonography in movement disorders: state of the art. Ultrasound Med Biol 2007;33:15-25.
22. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 2001;56:13-17.
23. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology 2003;60: 74-77.
24. Tatsch K, Asenbaum S, Bartenstein P, et al. European association of nuclear medicine procedure guidelines for brain neurotransmission neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. Eur J Nucl Med Mol Imaging 2002;29:BP30-35.
25. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978;25:638-643.
26. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000; 15:692-698.
27. Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease. Mov Disord 2006;21:94-98.
28. Doepp F, Plotkin M, Siegel L, et al. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor. Mov Disord 2008;23:405-410.
29. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995;45:182-184.
30. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005;20:383-385.
31. Walter U, Dressler D, Wolters A, Wittstock M, Benecke R. Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease. Mov Disord 2007;22:48-54.
32. Tolosa E, Katzenschlager R. Pharmacological management of Parkinson's disease. In: Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Philadelphia: Lippincott Williams & Wilkins; 2007. p110-145.
33. Iova A, Garmashov A, Androuchtchenko N, et al. Postnatal decrease in substantia nigra echogenicity. Implications for the pathogenesis of Parkinson's disease. J Neurol 2004;251:1451-1454.
34. Oakley AE, Collingwood JF, Dobson J, et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007;68:1820-1825.
35. Morris CM, Edwardson JA. Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration 1994;3:277-282.
36. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994;63:793-807.
37. Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann NY Acad Sci 2004;1012:193-208.
38. Michaeli S, Oz G, Sorce DJ, et al. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 2007;22:334-340.
39. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008;70(16 Pt 2):1411-1417.
40. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 2007;22:839-842.
41. Marsden CD. Parkinson's disease. Lancet 1990;335:948-952.
42. Hagenah JM, König IR, Becker B, et al. Substantia nigra hyperechogenicity correlates with clinical status and number of Parkin mutated alleles. J Neurol 2007;254:1407-1413.